ClinicalTrials.gg
Active, not recruitingNCT06795048CONSTANCEUpdated Oct 27, 2026

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

A Phase 4 interventional study of Faricimab in Neovascular Age-related Macular Degeneration (nAMD), sponsored by Hoffmann-La Roche. Active, not recruiting at 67 sites in 12 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Updated Oct 27, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
274
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing faricimab in Macular Degeneration — 6 open to participants now, 7 under way, 2 of them phase 3. faricimab · Macular Degeneration.

Planned enrollment
2nd of 14
274 · median 57
Started
2025
with 2 others
Phase 4
5 of 14
3 open now
Registered
8th of 14
by date
Lead sponsor
5 of 14
Hoffmann-La Roche

Among the 14 studies testing faricimab in Macular Degeneration, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2025, is one of 5 in phase 4, and was the 8th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

6 of the 14 studies testing faricimab in Macular Degeneration are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About faricimab

faricimab: first FDA approval 2022 (VABYSMO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing faricimab in Macular Degeneration, or all of them as a file.
02

Study summary

This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-week intervals in patients with neovascular age-related macular degeneration (nAMD) that are treatment-naïve in the study eye.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration (nAMD)
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overtly healthy as determined by medical evaluation that includes medical history and physical examination
  • Agreement to adhere to the requirements described in the protocol

Ocular Inclusion Criteria for Study Eye:

  • Active treatment-naïve macular neovascularization (MNV) secondary to age-related macular degeneration (AMD), confirmed by the investigator based on the presence of intraretinal fluid (IRF) or subretinal fluid (SRF) affecting the central subfield on optical coherence tomography (OCT)
  • BCVA of 83 to 24 letters, inclusive (20/25 to 20/320 approximate Snellen equivalent, using the early treatment diabetic retinopathy study [ETDRS] protocol and addressed at the initial testing distance of 4 meters on Day 1)
  • Sufficiently clear ocular media and adequate pupillary dilation to allow acquisition of good quality retinal images to confirm diagnosis

Exclusion criteria

Exclusion Criteria:

Ocular Exclusion Criteria for Study Eye:

  • MNV due to causes other than nAMD, such as ocular histoplasmosis, trauma, pathological myopia, angioid streaks, choroidal rupture, or uveitis
  • Retinal pigment epithelial tear involving the macula on Day 1
  • Current vitreous hemorrhage on Day 1
  • Prior periocular pharmacological or IVT treatment (including faricimab, anti-vascular endothelial growth factor [VEGF], or complement inhibitor medication) for other retinal diseases

Ocular Exclusion Criteria for Fellow (Non-Study) Eye:

  • Participants who have a nonfunctioning fellow (non-study) eye, defined as either BCVA of hand motion or worse, or no physical presence of non-study eye (i.e., monocular), at both the screening and study Day 1 visits

Ocular Exclusion for Both Eyes:

  • History of idiopathic or associated uveitis in either eye
  • Active ocular inflammation or suspected or active ocular or periocular infection in either eye on study Day 1
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
274 participants (estimated)

Study arms

  • Experimental
    Arm A: Faricimab Early Treat & Extend Regimen

    Drug: Faricimab

  • Experimental
    Arm B: Faricimab Modified Treat & Extend Regimen

    Drug: Faricimab

Interventions

  • Participants will receive 6-mg faricimab intravitreal (IVT) injections in the study eye according to the dosing regimen for the study arm to which they are randomized.

    Also known as: RO6867461, VABYSMO®

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Best-Corrected Visual Acuity (BCVA) Score Averaged Over Weeks 44, 48, and 52

    Time frame: Baseline and average of Weeks 44, 48, and 52

Secondary outcomes

  1. Change from Baseline in BCVA Score Averaged Over Weeks 92, 96, and 100

    Time frame: Baseline and average of Weeks 92, 96, and 100

  2. Change from Baseline in BCVA Score Over Time

    Time frame: From Baseline to Week 100

  3. Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA from Baseline Over Time

    Time frame: From Baseline to Week 100

  4. Percentage of Participants with BCVA Snellen Equivalent of 20/40 or Better Over Time

    Time frame: From Baseline to Week 100

  5. Percentage of Participants with BCVA Snellen Equivalent of 20/200 or Worse Over Time

    Time frame: From Baseline to Week 100

  6. Change from Baseline in Central Subfield Thickness (CST) Averaged Over Weeks 44, 48, and 52

    Time frame: Baseline and average of Weeks 44, 48, and 52

  7. Change from Baseline in CST Averaged Over Weeks 92, 96, and 100

    Time frame: Baseline and average of Weeks 92, 96, and 100

  8. Change from Baseline in CST Over Time

    Time frame: From Baseline to Week 100

  9. Percentage of Participants on Different Treatment Intervals at Weeks 52 and 100

    Time frame: Weeks 52 and 100

  10. Incidence and Severity of Ocular Adverse Events

    Time frame: From first study treatment to Week 100

  11. Incidence and Severity of Non-Ocular Adverse Events

    Time frame: From first study treatment to Week 100

07

Study locations

67 sites
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Oct 2026, 19 months.

Of 24 industry-sponsored phase 4 interventional studies under Macular Degeneration, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 19 months is below that.

Counting every sponsor, half of 45 studies reached it within 26 months; a quarter within 14 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2025
First posted
Jan 27, 2025
StartActual
Mar 14, 2025
Primary completionActual
Oct 16, 2026
CompletionEst.
Sep 20, 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 20, 2026→Oct 16, 2026 (actual)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Primary completion Oct 20, 2026→Oct 16, 2026 (now actual)
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06795048
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 27, 2025
Start date
Mar 14, 2025
Primary completion
Oct 16, 2026
Completion
Sep 20, 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Faricimab

Start the discussion